Treatment of Metastatic Urothelial Cancer in 2018

JAMA Oncol. 2019 Jun 1;5(6):904-905. doi: 10.1001/jamaoncol.2019.0182.

Authors

Joaquim Bellmunt^{1

2}, Alejo Rodriguez-Vida¹

Affiliations

¹ Medical Oncology Department, Hospital del Mar, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
² Dana-Farber Cancer Institute/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts.

PMID: 30973581
DOI: 10.1001/jamaoncol.2019.0182

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
Carboplatin / therapeutic use
Cisplatin / therapeutic use
Deoxycytidine / analogs & derivatives
Deoxycytidine / therapeutic use
Gemcitabine
Humans
Immunotherapy
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Taxoids / therapeutic use
Urologic Neoplasms / drug therapy*
Urologic Neoplasms / pathology
Urothelium / pathology*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Taxoids
Deoxycytidine
Carboplatin
Cisplatin
Gemcitabine